Trial Outcomes & Findings for Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (NCT NCT04624243)
NCT ID: NCT04624243
Last Updated: 2025-08-22
Results Overview
The PANSS assesses the severity of schizophrenia symptoms through a 30-item clinician-rated inventory organized into a positive subscale (7 items), a negative subscale (7 items) and a general psychopathology subscale (16 items). For each item, symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranges from 30 (lowest total score) to 210 (highest total score). Higher and lower change scores reflect symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
499 participants
Primary outcome timeframe
Baseline and Week 6
Results posted on
2025-08-22
Participant Flow
Participants were enrolled and randomized at 75 study sites in 11 countries.
Randomization into the MK-8189 8 mg arm ceased as of Amendment 4.
Participant milestones
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg once daily (QD) from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
41
|
132
|
132
|
65
|
129
|
|
Overall Study
COMPLETED
|
14
|
64
|
61
|
37
|
70
|
|
Overall Study
NOT COMPLETED
|
27
|
68
|
71
|
28
|
59
|
Reasons for withdrawal
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg once daily (QD) from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Overall Study
Death
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
Lost to Follow-up
|
2
|
3
|
7
|
1
|
3
|
|
Overall Study
Physician Decision
|
3
|
8
|
15
|
2
|
11
|
|
Overall Study
Withdrawal by Subject
|
19
|
44
|
40
|
21
|
39
|
|
Overall Study
Miscellaneous
|
3
|
12
|
9
|
4
|
6
|
Baseline Characteristics
Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Baseline characteristics by cohort
| Measure |
MK-8189 8 mg
n=41 Participants
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=132 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=132 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=65 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=129 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
Total
n=499 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
35.7 Years
STANDARD_DEVIATION 8.9 • n=5 Participants
|
39.4 Years
STANDARD_DEVIATION 9.0 • n=7 Participants
|
36.9 Years
STANDARD_DEVIATION 9.2 • n=5 Participants
|
38.5 Years
STANDARD_DEVIATION 9.6 • n=4 Participants
|
40.2 Years
STANDARD_DEVIATION 9.1 • n=21 Participants
|
38.5 Years
STANDARD_DEVIATION 9.3 • n=8 Participants
|
|
Sex: Female, Male
Female
|
12 Participants
n=5 Participants
|
46 Participants
n=7 Participants
|
42 Participants
n=5 Participants
|
25 Participants
n=4 Participants
|
42 Participants
n=21 Participants
|
167 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
29 Participants
n=5 Participants
|
86 Participants
n=7 Participants
|
90 Participants
n=5 Participants
|
40 Participants
n=4 Participants
|
87 Participants
n=21 Participants
|
332 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
11 Participants
n=21 Participants
|
40 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
40 Participants
n=5 Participants
|
117 Participants
n=7 Participants
|
121 Participants
n=5 Participants
|
61 Participants
n=4 Participants
|
118 Participants
n=21 Participants
|
457 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
12 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Black or African American
|
18 Participants
n=5 Participants
|
59 Participants
n=7 Participants
|
59 Participants
n=5 Participants
|
29 Participants
n=4 Participants
|
57 Participants
n=21 Participants
|
222 Participants
n=8 Participants
|
|
Race (NIH/OMB)
White
|
20 Participants
n=5 Participants
|
68 Participants
n=7 Participants
|
70 Participants
n=5 Participants
|
34 Participants
n=4 Participants
|
66 Participants
n=21 Participants
|
258 Participants
n=8 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Baseline and Week 6Population: All participants who receive ≥1 dose of MK-8189 (16 mg or 24 mg), risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included. Per protocol, the effect of the 8 mg dose was not assessed.
The PANSS assesses the severity of schizophrenia symptoms through a 30-item clinician-rated inventory organized into a positive subscale (7 items), a negative subscale (7 items) and a general psychopathology subscale (16 items). For each item, symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranges from 30 (lowest total score) to 210 (highest total score). Higher and lower change scores reflect symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=85 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=68 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=42 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=91 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
|
—
|
-20.7 Score on a scale
Interval -24.1 to -17.3
|
-18.5 Score on a scale
Interval -22.1 to -15.0
|
-24.0 Score on a scale
Interval -28.8 to -19.2
|
-17.8 Score on a scale
Interval -21.2 to -14.5
|
PRIMARY outcome
Timeframe: Up to Week 6Population: All participants who received ≥1 dose of study intervention are included.
An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, events were assessed for the first 6 weeks of treatment.
Outcome measures
| Measure |
MK-8189 8 mg
n=41 Participants
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=132 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=132 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=65 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=129 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
|
29 Participants
|
85 Participants
|
94 Participants
|
31 Participants
|
70 Participants
|
PRIMARY outcome
Timeframe: Up to Week 6Population: All participants who received ≥1 dose of study intervention are included.
An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, events were assessed for the first 6 weeks of treatment.
Outcome measures
| Measure |
MK-8189 8 mg
n=41 Participants
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=132 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=132 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=65 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=129 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Number of Participants Who Discontinued From Study Intervention Due to AE
|
8 Participants
|
17 Participants
|
33 Participants
|
8 Participants
|
16 Participants
|
SECONDARY outcome
Timeframe: Baseline and Week 6Population: All participants who received ≥1 dose of MK-8189 (16 mg or 24 mg), risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included. Per protocol, the effect of the 8 mg dose was not assessed.
The PANSS Positive Subscale (PSS) assesses the severity of schizophrenia symptoms. The PANSS PSS score was calculated as the sum of the rating assigned to each of the 7 PSS items and ranges from 7 (lowest total score) to 49 (highest total score). Higher and lower change scores reflect symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=85 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=68 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=42 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=91 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in PANSS Positive Subscale (PSS) Score at Week 6
|
—
|
-7.1 Score on a scale
Interval -8.2 to -6.0
|
-7.2 Score on a scale
Interval -8.3 to -6.0
|
-7.7 Score on a scale
Interval -9.3 to -6.1
|
-5.8 Score on a scale
Interval -6.9 to -4.7
|
SECONDARY outcome
Timeframe: Baseline and Week 6Population: All participants who received ≥1 dose of MK-8189 (16 mg or 24 mg), risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included. Per protocol, the effect of the 8 mg dose was not assessed.
The CGI-S is a single item 7-point clinician rated scale for assessing the global severity of the participant's illness. CGI-S scores range from 1 (participant normal, not ill) to 7 (participant extremely ill); higher and lower change from baseline scores indicate symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=83 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=68 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=42 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=88 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 6
|
—
|
-1.1 Score on a scale
Interval -1.3 to -0.9
|
-1.0 Score on a scale
Interval -1.2 to -0.8
|
-1.3 Score on a scale
Interval -1.5 to -1.0
|
-1.0 Score on a scale
Interval -1.2 to -0.8
|
SECONDARY outcome
Timeframe: Baseline and Week 12Population: All participants who received ≥1 dose of MK-8189, risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included.
The change from baseline in body weigh was determined at Week 12. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
n=12 Participants
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=56 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=45 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=34 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=52 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in Body Weight at Week 12
|
-3.2 Kilograms
Standard Deviation 5.4
|
-5.0 Kilograms
Standard Deviation 5.6
|
-2.9 Kilograms
Standard Deviation 5.1
|
2.7 Kilograms
Standard Deviation 3.8
|
-2.0 Kilograms
Standard Deviation 3.9
|
SECONDARY outcome
Timeframe: Baseline and Week 6Population: All participants who received ≥1 dose of MK-8189, risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included.
The change from baseline in body weigh was determined at Week 6. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
n=19 Participants
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=86 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=75 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=44 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=91 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in Body Weight at Week 6
|
-1.1 Kilograms
Standard Deviation 3.0
|
-3.2 Kilograms
Standard Deviation 4.1
|
-2.4 Kilograms
Standard Deviation 3.8
|
2.6 Kilograms
Standard Deviation 3.4
|
0.5 Kilograms
Standard Deviation 3.5
|
SECONDARY outcome
Timeframe: Baseline and Week 12Population: All participants who received ≥1 dose of MK-8189 (16 or 24 mg), risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included. Per protocol, the 8 mg arm was excluded from analysis.
The change from baseline in body weigh was determined at Week 12. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=56 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=45 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=34 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=52 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in Body Weight at Week 12: Model-based Analysis
|
—
|
-5.4 Kilograms
Interval -6.5 to -4.4
|
-4.3 Kilograms
Interval -5.4 to -3.2
|
3.0 Kilograms
Interval 1.6 to 4.4
|
-2.3 Kilograms
Interval -3.4 to -1.3
|
SECONDARY outcome
Timeframe: Baseline and Week 6Population: All participants who received ≥1 dose of MK-8189 (16 or 24 mg), risperidone, or placebo, and have both a baseline measurement and ≥1 valid post-baseline assessment, are included. Per protocol, the 8 mg arm was excluded from analysis.
The change from baseline in body weigh was determined at Week 6. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Outcome measures
| Measure |
MK-8189 8 mg
Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 16 mg
n=86 Participants
Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
MK-8189 24 mg
n=75 Participants
Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Risperidone 6 mg
n=44 Participants
Participants received risperidone 6 mg QD from Weeks 1 to 12, with 2 weeks of follow-up.
|
Placebo and MK-8189 24 mg
n=91 Participants
Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
|
|---|---|---|---|---|---|
|
Change From Baseline in Body Weight at Week 6: Model-based Analysis
|
—
|
-3.2 Kilograms
Interval -3.9 to -2.5
|
-2.8 Kilograms
Interval -3.5 to -2.1
|
2.8 Kilograms
Interval 1.8 to 3.8
|
0.5 Kilograms
Interval -0.2 to 1.2
|
Adverse Events
MK-8189 8 mg Weeks 1 to 6
Serious events: 1 serious events
Other events: 18 other events
Deaths: 0 deaths
MK-8189 16 mg Weeks 1 to 6
Serious events: 8 serious events
Other events: 58 other events
Deaths: 0 deaths
MK-8189 24 mg Weeks 1 to 6
Serious events: 6 serious events
Other events: 72 other events
Deaths: 0 deaths
Risperidone 6 mg Weeks 1 to 6
Serious events: 2 serious events
Other events: 19 other events
Deaths: 0 deaths
Placebo Weeks 1 to 6
Serious events: 0 serious events
Other events: 45 other events
Deaths: 0 deaths
MK-8189 8 mg Weeks 7 to 12
Serious events: 3 serious events
Other events: 4 other events
Deaths: 0 deaths
MK-8189 16 mg Weeks 7 to 12
Serious events: 4 serious events
Other events: 18 other events
Deaths: 1 deaths
MK-8189 24 mg Weeks 7 to 12
Serious events: 3 serious events
Other events: 10 other events
Deaths: 0 deaths
Risperidone 6 mg Weeks 7 to 12
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
MK-8189 24 mg Weeks 7 to 12 (Placebo Weeks 1 to 6)
Serious events: 2 serious events
Other events: 25 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
MK-8189 8 mg Weeks 1 to 6
n=41 participants at risk
Participants received MK-8189 8 mg QD from Weeks 1 to 6.
|
MK-8189 16 mg Weeks 1 to 6
n=132 participants at risk
Participants (who received MK-8189 16 mg Weeks 1 to 6) received MK-8189 16 mg QD from Weeks 1 to 6.
|
MK-8189 24 mg Weeks 1 to 6
n=132 participants at risk
Participants received MK-8189 24 mg QD from Weeks 1 to 6.
|
Risperidone 6 mg Weeks 1 to 6
n=65 participants at risk
Participants received risperidone 6 mg QD from Weeks 1 to 6.
|
Placebo Weeks 1 to 6
n=129 participants at risk
Participants received placebo QD from Weeks 1 to 6.
|
MK-8189 8 mg Weeks 7 to 12
n=17 participants at risk
Participants (who received MK-8189 8 mg Weeks 1 to 6) received MK-8189 8 mg QD from Weeks 7 to 12.
|
MK-8189 16 mg Weeks 7 to 12
n=75 participants at risk
Participants (who received MK-8189 16 mg Weeks 1 to 6) received MK-8189 16 mg QD from Weeks 7 to 12.
|
MK-8189 24 mg Weeks 7 to 12
n=60 participants at risk
Participants (who received MK-8189 24 mg) received MK-8189 24 mg QD from Weeks 7 to 12.
|
Risperidone 6 mg Weeks 7 to 12
n=39 participants at risk
Participants (who received risperidone 6 mg Weeks 1 to 6) received risperidone 8 mg QD from Weeks 7 to 12.
|
MK-8189 24 mg Weeks 7 to 12 (Placebo Weeks 1 to 6)
n=85 participants at risk
Participants (who received placebo Weeks 1 to 6) received MK-8189 24 mg Weeks 7 to 12.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Infections and infestations
Abscess limb
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Musculoskeletal and connective tissue disorders
Muscle rigidity
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Completed suicide
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Psychotic disorder
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Schizophrenia
|
2.4%
1/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
2/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.8%
5/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
11.8%
2/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.0%
3/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.3%
2/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.4%
2/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
1/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Nervous system disorders
Syncope
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
Other adverse events
| Measure |
MK-8189 8 mg Weeks 1 to 6
n=41 participants at risk
Participants received MK-8189 8 mg QD from Weeks 1 to 6.
|
MK-8189 16 mg Weeks 1 to 6
n=132 participants at risk
Participants (who received MK-8189 16 mg Weeks 1 to 6) received MK-8189 16 mg QD from Weeks 1 to 6.
|
MK-8189 24 mg Weeks 1 to 6
n=132 participants at risk
Participants received MK-8189 24 mg QD from Weeks 1 to 6.
|
Risperidone 6 mg Weeks 1 to 6
n=65 participants at risk
Participants received risperidone 6 mg QD from Weeks 1 to 6.
|
Placebo Weeks 1 to 6
n=129 participants at risk
Participants received placebo QD from Weeks 1 to 6.
|
MK-8189 8 mg Weeks 7 to 12
n=17 participants at risk
Participants (who received MK-8189 8 mg Weeks 1 to 6) received MK-8189 8 mg QD from Weeks 7 to 12.
|
MK-8189 16 mg Weeks 7 to 12
n=75 participants at risk
Participants (who received MK-8189 16 mg Weeks 1 to 6) received MK-8189 16 mg QD from Weeks 7 to 12.
|
MK-8189 24 mg Weeks 7 to 12
n=60 participants at risk
Participants (who received MK-8189 24 mg) received MK-8189 24 mg QD from Weeks 7 to 12.
|
Risperidone 6 mg Weeks 7 to 12
n=39 participants at risk
Participants (who received risperidone 6 mg Weeks 1 to 6) received risperidone 8 mg QD from Weeks 7 to 12.
|
MK-8189 24 mg Weeks 7 to 12 (Placebo Weeks 1 to 6)
n=85 participants at risk
Participants (who received placebo Weeks 1 to 6) received MK-8189 24 mg Weeks 7 to 12.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Headache
|
9.8%
4/41 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
9.1%
12/132 • Number of events 12 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
8.3%
11/132 • Number of events 13 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.2%
4/65 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
9.3%
12/129 • Number of events 12 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.7%
2/75 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.3%
2/60 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.1%
2/39 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.7%
4/85 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Agitation
|
9.8%
4/41 • Number of events 5 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.3%
7/132 • Number of events 8 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/132 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.6%
2/129 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.2%
1/85 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Gastrointestinal disorders
Constipation
|
2.4%
1/41 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.3%
7/132 • Number of events 7 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/132 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.9%
5/129 • Number of events 6 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
1/17 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.7%
2/75 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Gastrointestinal disorders
Diarrhoea
|
7.3%
3/41 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.5%
6/132 • Number of events 6 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/132 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.9%
5/129 • Number of events 5 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.6%
1/39 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.5%
3/85 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Gastrointestinal disorders
Nausea
|
4.9%
2/41 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
15.9%
21/132 • Number of events 25 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
18.9%
25/132 • Number of events 30 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
9.2%
6/65 • Number of events 11 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.7%
6/129 • Number of events 7 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.0%
3/75 • Number of events 6 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.3%
2/60 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
5/85 • Number of events 5 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Gastrointestinal disorders
Toothache
|
7.3%
3/41 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.76%
1/132 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.1%
2/65 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.78%
1/129 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.6%
1/39 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Gastrointestinal disorders
Vomiting
|
9.8%
4/41 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
12.1%
16/132 • Number of events 21 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
13.6%
18/132 • Number of events 34 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.4%
7/129 • Number of events 8 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.3%
4/75 • Number of events 5 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.3%
2/60 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.4%
2/85 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/132 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/132 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/129 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.1%
2/39 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.4%
2/85 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.1%
2/39 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Investigations
Weight increased
|
2.4%
1/41 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.6%
3/65 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.3%
3/129 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.1%
2/39 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.2%
1/85 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Nervous system disorders
Akathisia
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.1%
8/132 • Number of events 9 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
9.1%
12/132 • Number of events 12 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.2%
4/65 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.6%
2/129 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.7%
4/85 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Nervous system disorders
Dystonia
|
4.9%
2/41 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.0%
4/132 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.8%
9/132 • Number of events 10 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.2%
1/85 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Anxiety
|
4.9%
2/41 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.1%
8/132 • Number of events 8 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
9.8%
13/132 • Number of events 13 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.2%
4/65 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.2%
8/129 • Number of events 12 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.7%
2/75 • Number of events 3 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
2.6%
1/39 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.7%
4/85 • Number of events 5 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Insomnia
|
9.8%
4/41 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.3%
7/132 • Number of events 11 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
7.6%
10/132 • Number of events 13 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
6.2%
8/129 • Number of events 8 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
9.3%
7/75 • Number of events 7 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.3%
2/60 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.7%
4/85 • Number of events 4 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Psychiatric disorders
Schizophrenia
|
4.9%
2/41 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
4.5%
6/132 • Number of events 6 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
8.3%
11/132 • Number of events 11 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
3.1%
2/65 • Number of events 2 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.4%
7/129 • Number of events 7 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/17 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
7.1%
6/85 • Number of events 6 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
1/17 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.78%
1/129 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
1/17 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.3%
1/75 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.5%
1/65 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.78%
1/129 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
1/17 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
1.7%
1/60 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/41 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/132 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/65 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/129 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
5.9%
1/17 • Number of events 1 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/75 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/60 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/39 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
0.00%
0/85 • Up to ~14 weeks
All treated participants are included. To accommodate the different treatments in the "Placebo and MK-8189 24 mg", data from Weeks 1 to 6 and Weeks 7 to 12 are presented separately.
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme LLC
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.
- Publication restrictions are in place
Restriction type: OTHER